J M Kirkwood

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features
    T Clark Gamblin
    Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Ann Surg Oncol 13:1664-70. 2006
  2. doi request reprint Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
  3. doi request reprint A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 113:1632-40. 2008
  4. ncbi request reprint Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pennsylvania, USA
    Cancer 95:1101-12. 2002
  5. ncbi request reprint Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    John M Kirkwood
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:3703-18. 2002
  6. ncbi request reprint High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    J M Kirkwood
    Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 18:2444-58. 2000
  7. ncbi request reprint High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
    J M Kirkwood
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute Melanoma Center, Department of Medicine, Division of Hematology Oncology, Pittsburgh, PA, USA
    J Clin Oncol 19:1430-6. 2001
  8. pmc Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
    H M Zarour
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:400-5. 2000
  9. ncbi request reprint High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
    J M Kirkwood
    Division of Hematology Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 19:2370-80. 2001
  10. ncbi request reprint NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
    H M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Cancer Res 60:4946-52. 2000

Detail Information

Publications79

  1. ncbi request reprint Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features
    T Clark Gamblin
    Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Ann Surg Oncol 13:1664-70. 2006
    ..Sentinel lymph node biopsy (SLNB) is routinely used as a staging procedure for melanomas, however may also assist in understanding the biology of atypical and controversial spitzoid melanocytic skin lesions...
  2. doi request reprint Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...
  3. doi request reprint A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 113:1632-40. 2008
    ..Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy...
  4. ncbi request reprint Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pennsylvania, USA
    Cancer 95:1101-12. 2002
    ....
  5. ncbi request reprint Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    John M Kirkwood
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:3703-18. 2002
    ..It is important to understand the expected adverse events and their underlying mechanisms and to anticipate and aggressively manage toxicity during treatment in order to ensure that patients receive the maximum therapeutic benefit...
  6. ncbi request reprint High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    J M Kirkwood
    Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 18:2444-58. 2000
    ..Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS) benefit compared with observation (Obs)...
  7. ncbi request reprint High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
    J M Kirkwood
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute Melanoma Center, Department of Medicine, Division of Hematology Oncology, Pittsburgh, PA, USA
    J Clin Oncol 19:1430-6. 2001
    ....
  8. pmc Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
    H M Zarour
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:400-5. 2000
    ..Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4(+) T cell responses against melanoma in vivo...
  9. ncbi request reprint High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
    J M Kirkwood
    Division of Hematology Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 19:2370-80. 2001
    ....
  10. ncbi request reprint NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
    H M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Cancer Res 60:4946-52. 2000
    ....
  11. pmc Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis
    H A Tawbi
    Department of Medicine Division of Hematology Oncology, School of Medicine, University of Pittsburgh, Pittsburgh 15232, USA
    Ann Oncol 24:1112-9. 2013
    ....
  12. pmc gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells
    L S Kierstead
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Br J Cancer 85:1738-45. 2001
    ..Based on these data, these epitopes may serve as potent vaccine components to promote clinically-relevant Th1-type CD4+ T cell effector function in situ...
  13. ncbi request reprint Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690
    U N M Rao
    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 20:2053-7. 2002
    ....
  14. pmc Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
    H A Tawbi
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Br J Cancer 105:773-7. 2011
    ..Depletion of MGMT can be achieved using O6-meG pseudosubstrates. Herein, we report the first phase I experience of the novel O6-meG pseudosubstrate lomeguatrib, combined with dacarbazine...
  15. ncbi request reprint IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro
    L Vujanovic
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 13:798-805. 2006
    ..Based on these results, we believe this modality may prove clinically useful as a vaccine platform to promote the recovery of tumor antigen-specific, Th1-type CD4(+) T-cell responses in patients with cancer...
  16. ncbi request reprint SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas
    S J Moschos
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Oncogene 26:4216-25. 2007
    ....
  17. ncbi request reprint Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections
    A I Dow
    Center for Light Microscope Imaging and Biotechnology, Carnegie Mellon University, University of Pittsburgh Cancer Institute, PA 15213, USA
    Cytometry 25:71-81. 1996
    ..The multiparameter fluorescent technique enables simultaneous determination of multiple cell subsets and can provide the spatial relationships of each cell type within the tissue...
  18. ncbi request reprint Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer
    S S Agarwala
    University of Pittsburgh Cancer Institute, PA, USA
    Cytokines Cell Mol Ther 6:171-6. 2000
    ..Loxoribine is safe at doses up to 10 mg/kg in patients with advanced cancer, and produces modest immunologic effects. Further testing, particularly in conjunction with other immunologic agents, is warranted...
  19. ncbi request reprint Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis
    C Esche
    Department of Pathology, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Clin Cancer Res 7:974s-979s. 2001
    ..We conclude that: (a) mature DCs might be more suitable for the use of cancer vaccination; and (b) Bcl-2 protein family members such as Bcl-xL and Bcl-2 rescue DCs from tumor-induced premature apoptosis...
  20. ncbi request reprint Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion
    R P Edwards
    University of Pittsburgh Cancer Institute, Magee Womens Hospital, University of Pittsburgh School of Medicine, PA 15213 3180, USA
    J Clin Oncol 15:3399-407. 1997
    ..To compare the toxicity, pharmacokinetics, and efficacy seen in ovarian cancer patients treated with escalating doses of intraperitoneal (I.P.) interleukin-2 (IL-2) by two different infusion schedules...
  21. ncbi request reprint Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma
    S S Agarwala
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Oncologist 5:144-51. 2000
    ..Therefore, TMZ is actively being investigated for the treatment and prevention of brain metastases in melanoma patients. TMZ may become an important part of treatment regimens for advanced metastatic melanoma...
  22. ncbi request reprint Targeted therapy for malignant melanoma
    C K Brown
    Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, 200 Lothrop Street, N-758 MUH, Pittsburgh, PA 15213-2582, USA
    Curr Oncol Rep 3:344-52. 2001
    ..This work has furthered our understanding of the basis of malignancy, as well as the development of novel strategies aimed at targeting aberrant growth in melanoma...
  23. ncbi request reprint Prognostic significance of autoimmunity during treatment of melanoma with interferon
    Helen Gogas
    First Department of Medicine, Laiko Hospital, Athens, Greece
    N Engl J Med 354:709-18. 2006
    ..We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b...
  24. ncbi request reprint Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents
    Stergios J Moschos
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, PA 15213 2584, USA
    Melanoma Res 17:193-200. 2007
    ..Better laboratory correlates of antiangiogenic response are needed, and the predictive value of circulating endothelial cells warrants further evaluation...
  25. ncbi request reprint Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b
    Zoya R Yurkovetsky
    University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Clin Cancer Res 13:2422-8. 2007
    ..Development of reliable serum assays may contribute to the development of methods for earlier detection of melanoma and the selection of patients who may be most susceptible to current available interventions with IFNalpha...
  26. ncbi request reprint Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute Pittsburgh, PA, USA
    Clin Cancer Res 13:1523-31. 2007
    ..The goal of this study was to understand the effects of high-dose IFNalpha2b (HDI) in relation to the balance of pSTAT1 and pSTAT3...
  27. ncbi request reprint Molecularly targeted therapy for melanoma: current reality and future options
    Jurgen C Becker
    Department of Dermatology, Julius Maximilians University, Wurzburg, Germany
    Cancer 107:2317-27. 2006
    ..Among the possible targets in melanoma are the Ras-MAPK and PI3K/AKT signal transduction pathways, the proteasome, histone deacetylases, methyltransferases, and melanoma-induced angiogenesis...
  28. ncbi request reprint Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
    Stergios J Moschos
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 24:3164-71. 2006
    ..Therefore, HDI was investigated in the neoadjuvant setting to assess clinical and pathologic responses after 4 weeks of HDI and to perform immunohistochemical evaluation of immune cell subsets and melanoma-associated antigens...
  29. ncbi request reprint Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b"
    Ahmad A Tarhini
    Oncologist 11:538-9; author reply 539-40. 2006
  30. ncbi request reprint Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations
    John M Kirkwood
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 12:2331s-2336s. 2006
    ..These new insights will allow us to develop more efficient approaches to adjuvant therapy of melanoma, focusing on autoimmunity and antitumor immunity with new immunomodulators, such as anti-CTLA4 antibodies and vaccination...
  31. ncbi request reprint Innovations and challenges in melanoma: summary statement from the first Cambridge conference
    Michael B Atkins
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2291s-2296s. 2006
    ....
  32. ncbi request reprint Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 25:3802-7. 2007
    ..We conducted a phase II trial of high-dose bolus (HDB) interleukin-2 (IL-2) in patients with metastatic melanoma who had experienced progression after biochemotherapy (BCT)...
  33. doi request reprint STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy
    Wenjun Wang
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 2584, USA
    J Invest Dermatol 128:1997-2002. 2008
    ..pSTAT3 is a potential biomarker of melanocytic transformation and progression and is modulated by IFNalpha dose-dependently. STAT3 is a potential target for chemoprevention of melanoma...
  34. doi request reprint Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer 112:1131-8. 2008
    ..Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma...
  35. doi request reprint Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group
    Alessandro Testori
    Istituto Europeo di Oncologia, Milan, Italy
    J Clin Oncol 26:955-62. 2008
    ....
  36. doi request reprint Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion
    Axel Hauschild
    Department of Dermatology, University of Kiel, Kiel, Germany
    Cancer 112:982-94. 2008
    ..Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment...
  37. doi request reprint Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008
    ....
  38. ncbi request reprint Management of metastatic melanoma
    Hussein A Tawbi
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Semin Oncol 34:532-45. 2007
    ..The rational use of agents capable of abrogating drug resistance offers other opportunities for systemic chemotherapy that may then give rise to more rationally developed combinations...
  39. ncbi request reprint Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Nat Clin Pract Oncol 5:2-3. 2008
  40. ncbi request reprint Integrins and cancer
    Stergios J Moschos
    Department of Medicine, Division of Hematology Oncology, Melanoma and Skin Cancer Program, University of Pittsburgh, Cancer Institute, USA
    Oncology (Williston Park) 21:13-20. 2007
    ..Furthermore, it provides a synopsis on the clinical advancements in integrin targeting for therapeutic and imaging purposes in cancer...
  41. ncbi request reprint Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26
    Marie Diener-West
    Coordinating Center, Wilmer Clinical Trials and Biometry, 550 N Broadway, Ninth Floor, Baltimore, MD 21205, USA
    Arch Ophthalmol 123:1639-43. 2005
    ..To describe the time between treatment for choroidal melanoma and first diagnosis of metastatic disease, sites of metastasis, treatments for metastasis, and time between diagnosis of metastasis and death...
  42. ncbi request reprint Building upon the standard of care in adjuvant therapy of high-risk melanoma
    John M Kirkwood
    J Clin Oncol 23:8559-63. 2005
  43. ncbi request reprint Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited
    Kelly M McMasters
    Arch Dermatol 139:99; author reply 99-100. 2003
  44. ncbi request reprint Use and abuse of statistics in evidence-based medicine
    John M Kirkwood
    J Clin Oncol 20:4122-3; author reply 4123-4. 2002
  45. ncbi request reprint Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Onco
    Sanjiv S Agarwala
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Cancer 100:1692-8. 2004
    ....
  46. ncbi request reprint A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
    John M Kirkwood
    University of Pittsburgh Medical Center, Department of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 10:1670-7. 2004
    ..The objectives of this study were to update the analyses of each individual trial and to analyze prognostic factors and treatment effects based on pooled data...
  47. ncbi request reprint Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b
    Stergios J Moschos
    J Clin Oncol 22:11-4. 2004
  48. ncbi request reprint New TNM melanoma staging system: linking biology and natural history to clinical outcomes
    Charles M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Semin Surg Oncol 21:43-52. 2003
    ....
  49. ncbi request reprint Update on adjuvant interferon therapy for high-risk melanoma
    Sanjiv S Agarwala
    Melanoma Center, University of Pittsburgh Cancer Institute, USA
    Oncology (Williston Park) 16:1177-87; discussion 1190-2, 1197. 2002
    ..The use of surgical staging will help to better define prognostic groups and support ongoing efforts for more effective adjuvant therapy...
  50. ncbi request reprint Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study
    Sanjiv S Agarwala
    Melanoma Center, Cancer Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Cancer 97:121-7. 2003
    ....
  51. ncbi request reprint Adjuvant therapy of melanoma
    Larisa Geskin
    Department of Dermatology, University of Pittsburgh, Melanoma Center UPCI, Pittsburgh, PA 15213, USA
    Semin Cutan Med Surg 22:55-67. 2003
  52. ncbi request reprint Medical management of melanoma
    Charles Komen Brown
    Department of Surgery, University of Chicago, 5841 S Maryland Avenue MC6040, Chicago, IL 60637, USA
    Surg Clin North Am 83:283-322, viii. 2003
    ..Additionally, successes and failures of clinical trials will be discussed, as they will guide the strategic development of future studies in the management of this aggressive disease...
  53. ncbi request reprint MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Cancer Res 9:947-54. 2003
    ..These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma...
  54. ncbi request reprint Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study
    Sanjiv S Agarwala
    Division of Hematology Oncology, University of Pittsburgh Medical Center Pavilion, 5150 Centre Ave, Pittsburgh, PA 15232, USA
    J Clin Oncol 22:2101-7. 2004
    ..A multicenter, open-label, phase II study was conducted to assess the safety and efficacy of temozolomide in patients with brain metastases from metastatic melanoma (MM) who did not require immediate radiotherapy...
  55. pmc Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Exp Med 196:619-28. 2002
    ..Our data suggest that immunotherapeutic approaches will likely have to overcome or complement systemic Th2-dominated, tumor-reactive CD4(+) T cell responses to provide optimal clinical benefit...
  56. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  57. ncbi request reprint Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs
    Mohammed Islam
    Melanoma Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2480-7. 2002
    ..A significant inhibitory effect of HDI on CYP enzymes would increase the potential for adverse drug reactions and altered homeostasis through effects on hormone metabolism...
  58. ncbi request reprint Adjuvant high-dose interferon-alpha therapy for high-risk melanoma
    John M Kirkwood
    Division of Medical Oncology, University of Pittsburgh, 200 Lothrop Street, 15123 Pittsburg, Pennsylvania
    Forum (Genova) 13:127-40; quiz 187-8. 2003
    ..We also present selected ongoing trials testing potential future therapies that may prove effective for patients with high-risk resected melanoma...
  59. ncbi request reprint An evidence-based staging system for cutaneous melanoma
    Charles M Balch
    American Society of Clinical Oncology, Alexandria, VA, USA
    CA Cancer J Clin 54:131-49; quiz 182-4. 2004
    ..6) A new convention was implemented for defining clinical and pathological staging so as to take into account the new staging information gained from lymphatic mapping and sentinel node biopsy...
  60. ncbi request reprint Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
    Sanjiv S Agarwala
    Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 20:125-33. 2002
    ..This study was designed to determine whether the addition of histamine to a subcutaneous (SC) regimen of interleukin-2 (IL-2) would improve the survival of metastatic melanoma patients...
  61. ncbi request reprint Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data
    Kerry L Kilbridge
    Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, VA 22908 0821, USA
    J Clin Oncol 20:1311-8. 2002
    ....
  62. ncbi request reprint An update on adjuvant interferon for melanoma
    Richard J Gray
    Division of General Surgery, Mayo Clinic, Arizona, USA
    Cancer Control 9:16-21. 2002
    ..Effective adjuvant therapy is needed for this patient population...
  63. ncbi request reprint Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression
    Laura Strauss
    University of Pittsburgh Cancer Institute, Department of Medicine, School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 180:2967-80. 2008
    ..As CD4+CD25highFoxp3+ naturally occurring T regulatory cells in melanoma patients express ICOS, we investigated the impact of ICOS on naturally occurring T regulatory cell function...
  64. doi request reprint Resolving "kinks" of chemotherapy in melanoma
    Stergios J Moschos
    J Natl Cancer Inst 100:833-5. 2008
  65. doi request reprint Focus on FOCIS: interleukin 2 treatment associated autoimmunity
    Stergios J Moschos
    University of Pittsburgh Federation of Clinical Immunologic Societies Center of Excellence, Pittsburgh, Pennsylvania 15213 1683, USA
    Clin Immunol 127:123-9. 2008
    ..We present studies investigating the mechanisms for the therapeutic benefit of HDIL2 in melanoma...
  66. ncbi request reprint Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Avenue, Pittsburgh, PA 15213 2584, USA
    Cancer Immunol Immunother 57:1315-21. 2008
    ..We have therefore evaluated STAT3 and MEK/ERK MAP kinases in patients with regional lymph node metastasis (stage IIIB) of melanoma in the context of a prospective neoadjuvant trial of HDI (UPCI 00-008)...
  67. ncbi request reprint Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, PA 15213, USA
    Nat Clin Pract Oncol 2:240-1. 2005
  68. ncbi request reprint Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma
    Stergios Moschos
    Department of Medicine, University of Pittsburgh School of Medicine, Hillman Cancer Center, Research Pavilion, Suite L1 32c, 5117 Centre Avenue, Pittsburgh, PA 15213 2584, United States
    Cytokine Growth Factor Rev 18:451-8. 2007
    ..We discuss potential mechanisms that partially explain the clinical benefit, and set the groundwork for building upon, the design of more effective treatments for this disease...
  69. ncbi request reprint Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25
    Marie Diener-West
    COMS Coordinating Center, Wilmer Clinical Trials and Biometry, 550 N Broadway, Ninth Floor, Baltimore, MD 21205, USA
    Arch Ophthalmol 123:601-4. 2005
    ..To report sites of second primary cancer and the time to first diagnosis during routine follow-up after treatment for choroidal melanoma...
  70. ncbi request reprint Radiosurgery for the treatment of spinal melanoma metastases
    Peter C Gerszten
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Stereotact Funct Neurosurg 83:213-21. 2005
    ..This study evaluated the clinical efficacy of radiosurgery for the treatment of melanoma spinal metastases in 28 patients...
  71. ncbi request reprint Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation
    Anna Wankowicz-Kalinska
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Melanoma Res 16:165-74. 2006
    ....
  72. ncbi request reprint Melanoma in the older person
    Susan M Swetter
    Department of Dermatology, Pigmented Lesion and Cutaneous Melanoma Clinic, Stanford University Medical Center Veterans Affairs Palo Alto Health Care System, California 94305, USA
    Oncology (Williston Park) 18:1187-96; discussion 1196-7. 2004
    ..Secondary melanoma prevention should be focused on targeted education to older men and their spouses for early detection and reduction of mortality in this extremely high-risk group...
  73. ncbi request reprint Melanoma
    Stergios J Moschos
    The University of Pittsburgh, Cancer Institute, Melanoma Center, Pittsburgh, PA 15213 2584, USA
    Cancer Chemother Biol Response Modif 22:563-90. 2005
  74. ncbi request reprint Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver
    Sanjiv S Agarwala
    University of Pittsburgh Cancer Institute, 5th Floor, 5150 Centre Ave, Pittsburgh, PA 15232, USA
    Melanoma Res 14:217-22. 2004
    ..The overall response rate was 16%. Dose-limiting toxicities included renal, hepatic and haematological effects. This therapy produces a modest response rate in patients with ocular melanoma and liver metastases...
  75. ncbi request reprint Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress
    Demetrius M Kokkinakis
    Department of Pathology, University of Pittsburgh, Pennsylvania, USA
    Mol Cancer Res 4:575-89. 2006
    ..Although MDS targets several common genes in tumors, mutational variability among melanomas may decide which metabolic and signal transduction pathways will be activated or shutdown...
  76. ncbi request reprint Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
    Agop Y Bedikian
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 24:4738-45. 2006
    ..We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma...
  77. ncbi request reprint Chemotherapy for metastatic melanoma: time for a change?
    Helen J Gogas
    First Department of Internal Medicine, University of Athens, Athens, Greece
    Cancer 109:455-64. 2007
    ..They discuss roles of single-agent chemotherapy, combination chemotherapy, combinations of chemotherapy with immunomodulatory or hormone agents, biochemotherapy, and combination chemotherapy with targeted therapies...
  78. ncbi request reprint Melanoma vaccines: early progress and future promises
    Hassane M Zarour
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Semin Cutan Med Surg 22:68-75. 2003
    ....
  79. ncbi request reprint Oblimersen in the treatment of metastatic melanoma
    Ahmad A Tarhini
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, UPCI UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Future Oncol 3:263-71. 2007
    ..This article reviews the biochemistry, pharmacodynamics and pharmacokinetics, safety and efficacy data related to oblimersen in melanoma...